Which of the following is a recognized risk associated with SSRIs?

Bone loss is a recognized risk associated with selective serotonin reuptake inhibitors (SSRIs). Several studies have indicated that long-term use of SSRIs may be linked to decreased bone mineral density, increasing the risk of fractures and osteoporosis. This effect is thought to be mediated by the influence of serotonin on bone metabolism, where altered serotonin levels can impact the activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells).

Understanding the complexities of SSRIs is essential, as their primary use is in treating depression and anxiety, yet they can have unforeseen implications on bone health, particularly in populations such as older adults who may already be at risk for bone-related conditions. This highlights the importance of monitoring patients on SSRIs for potential adverse effects beyond the primary target symptoms.